Cust AE - Search Results

1

Beyond country-specific incidence and mortality: the global burden of melanoma.

Bell KJL, Cust AE. Bell KJL, et al. Among authors: cust ae. Br J Dermatol. 2018 Feb;178(2):315-316. doi: 10.1111/bjd.15688. Br J Dermatol. 2018. PMID: 29441534 No abstract available.

2

Clinical practice guidelines for identification, screening and follow-up of individuals at high risk of primary cutaneous melanoma: a systematic review.

Watts CG, Dieng M, Morton RL, Mann GJ, Menzies SW, Cust AE. Watts CG, et al. Among authors: cust ae. Br J Dermatol. 2015 Jan;172(1):33-47. doi: 10.1111/bjd.13403. Epub 2014 Dec 11. Br J Dermatol. 2015. PMID: 25204572 Review.

3

Increasing prevalence but not incidence of psoriasis in the U.K.

Cust AE, Murrell DF. Cust AE, et al. Br J Dermatol. 2017 Mar;176(3):568-569. doi: 10.1111/bjd.15331. Br J Dermatol. 2017. PMID: 28300313 No abstract available.

4

Estimating the future health service burden of keratinocyte cancers in the U.K.

Cust AE. Cust AE. Br J Dermatol. 2017 May;176(5):1107-1108. doi: 10.1111/bjd.15476. Br J Dermatol. 2017. PMID: 28504381 No abstract available.

5

Does personalized melanoma genomic risk information trigger conversations about skin cancer prevention and skin examination with family, friends and health professionals?

Smit AK, Keogh LA, Newson AJ, Butow PN, Dunlop K, Morton RL, Kirk J, Espinoza D, Cust AE. Smit AK, et al. Among authors: cust ae. Br J Dermatol. 2017 Sep;177(3):779-790. doi: 10.1111/bjd.15744. Epub 2017 Jul 20. Br J Dermatol. 2017. PMID: 28627002 Clinical Trial.

6

The Importance of Population-Based Estimates of Melanocytic Pathology.

Bell KJL, Cust AE, Scolyer RA. Bell KJL, et al. Among authors: cust ae. JAMA Dermatol. 2018 Jan 1;154(1):15-17. doi: 10.1001/jamadermatol.2017.4061. JAMA Dermatol. 2018. PMID: 29094157 No abstract available.

7

Prognostic features for acral lentiginous melanoma.

Cust AE. Cust AE. Br J Dermatol. 2018 Feb;178(2):311-312. doi: 10.1111/bjd.16163. Br J Dermatol. 2018. PMID: 29441559 No abstract available.

8

Why a randomized melanoma screening trial may be a good idea.

Cust AE, Aitken JF, Baade PD, Whiteman DC, Soyer HP, Janda M. Cust AE, et al. Br J Dermatol. 2018 Nov;179(5):1227-1228. doi: 10.1111/bjd.17089. Epub 2018 Sep 20. Br J Dermatol. 2018. PMID: 30101459 No abstract available.

9

Exploring the emotional and behavioural reactions to receiving personalized melanoma genomic risk information: a qualitative study.

Fenton GL, Smit AK, Keogh L, Cust AE. Fenton GL, et al. Among authors: cust ae. Br J Dermatol. 2019 Jun;180(6):1390-1396. doi: 10.1111/bjd.17582. Epub 2019 Mar 4. Br J Dermatol. 2019. PMID: 30580464 Clinical Trial.

10

Benefits of a brief psychological intervention targeting fear of cancer recurrence in people at high risk of developing another melanoma: 12-month follow-up results of a randomized controlled trial.

Dieng M, Morton RL, Costa DSJ, Butow PN, Menzies SW, Lo S, Mann GJ, Cust AE, Kasparian NA. Dieng M, et al. Among authors: cust ae. Br J Dermatol. 2020 Apr;182(4):860-868. doi: 10.1111/bjd.17990. Epub 2019 Jul 25. Br J Dermatol. 2020. PMID: 30965384 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

232 results

Search Page